Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]T Ram pias, C Sasaki, A Psyrri: Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol 50, 356-363 (2014)

  • [2]A K Chaturvedi, E A Engels, R M Pfeiffer, B Y Hernandez, W Xiao, E Kim, B Jiang, M T Goodman, M Sibug-Saber, W Cozen, L Liu, C F Lynch, N Wentzensen, R C Jordan, S Altekruse, W F Anderson, P S Rosenberg, M L Gillison: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29, 4294–4301 (2011)

  • [3]M Stanley: Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109, S15–21 (2008)

  • [4]C A DeCarlo, B Rosa, R Jackson, S Niccoli, N G Escott, I Zehbe: Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012, 785825 (2012)

  • [5]B Beutler: Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257–263 (2004)

  • [6]J Holldack: Toll-like receptors as therapeutic targets for cancer. Drug Discov Today 19, 379–382 (2014)

  • [7]U A Hasan, E Bates, F Takeshita, A Biliato, R Accardi, V Bouvard, M Mansour, I Vincent, L Gissmann, T Iftner, M Sideri, F Stubenrauch, M Tommasino: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178, 3186–3197 (2007)

  • [8]R Yang, F M Murillo, M J Delannoy, R L Blosser, W H Yutzy 4th, S Uematsu, K Takeda, S Akira, R P Viscidi, R B S Roden: B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174, 7912–7919 (2005)

  • [9]I I Daud, M E Scott, Y Ma, S Shiboski, S Farhat, A-B Moscicki: Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 128, 879–886 (2011)

  • [10]B Huang, J Zhao, H Li, K-L He, Y Chen, S-H Chen, L Mayer, J C Unkeless, H Xiong: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65, 5009–5014 (2005)

  • [11]G Gatti, A A Quintar, V Andreani, J P Nicola, C A Maldonado, A M Masini-Repiso, V E Rivero, M Maccioni: Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 69, 1387–1397 (2009)

  • [12]S González-Reyes, J M Fernández, L O González, A Aguirre, A Suárez, J M González, S Escaff, F J Vizoso: Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 60, 217–226 (2011)

  • [13]N Ehsan, S Murad, T Ashiq, M U Mansoor, S Gul, S Khalid, M Younas: Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol 34, 1053–1059 (2013)

  • [14]S Rajput, L D Volk-Draper, S Ran: TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12, 1676–1687 (2013)

  • [15]M Szajnik, M J Szczepanski, M Czystowska, E Elishaev, M Mandapathil, E Nowak-Markwitz, M Spaczynski, T L Whiteside: TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 28, 4353–4363 (2009)

  • [16]K H Kim, M S Jo, D S Suh, M S Yoon, D H Shin, J H Lee, K U Choi: Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol 10, 193 (2012)

  • [17]B Schmausser, M Andrulis, S Endrich, H-K Müller-Hermelink, M Eck: Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295, 179–185 (2005)

  • [18]E L Wang, Z R Qian, M Nakasono, T Tanahashi, K Yoshimoto, Y Bando, E Kudo, M Shimada, T Sano: High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102, 908–915 (2010)

  • [19]A Pinto, S Morello, R Sorrentino: Lung cancer and Toll-like receptors. Cancer Immunol Immunother 60, 1211–1220 (2011)

  • [20]Y-B Zhang, F-L He, M Fang, T-F Hua, B-D Hu, Z-H Zhang, Q Cao, R-Y Liu: Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 36, 1475–1481 (2009)

  • [21]N Eiró, C Ovies, B Fernandez-Garcia, C C Álvarez-Cuesta, L González, L O González, F J Vizoso: Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res 305, 59–67 (2013)

  • [22]L Yu, L Wang, M Li, J Zhong, Z Wang, S Chen: Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 59, 1021–1028 (2010)

  • [23]M Siponen, J H Kauppila, Y Soini, T Salo: TLR4 and TLR9 are induced in oral lichen planus. J Oral Pathol Med 41, 741–747 (2012)

  • [24]Y Mori, A Yoshimura, T Ukai, E Lien, T Espevik, Y Hara: Immunohistochemical localization of Toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Oral Microbiol Immunol 18, 4–8 (2003)

  • [25]L Ren, WK Leung, RP Darveau, L Jin: The expression profile of lipopolysaccharide-binding protein, membranebound CD14, and toll-like receptors 2 and 4 in chronic periodontitis. J Periodontol 76, 1950–1959 (2005)

  • [26]Y Sugawara, A Uehara, Y Fujimoto, S Kusumoto, K Fukase, K Shibata, S Sugawara, T Sasano, H Takada: Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res 85, 524–529 (2006)

  • [27]R Mahanonda, S Pichyangkul: Toll-like receptors and their role in periodontal health and disease. Periodontol 2000 43, 41–55 (2007)

  • [28]A Beklen, M Hukkanen, R Richardson, Y T Konttinen: Immunohistochemical localization of Toll-like receptors 1-10 in periodontitis. Oral Microbiol Immunol 23, 425–431 (2008)

  • [29]N R Rojo-Botello, A L García-Hernández, L Moreno-Fierros: Expression of toll-like receptors 2, 4 and 9 is increased in gingival tissue from patients with type 2 diabetes and chronic periodontitis. J Periodont Res 47, 62–73 (2012)

  • [30]A Uehara, S Sugawara, R Tamai, H Takada: Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD14. Med Microbiol Immunol 189, 185–192 (2001)

  • [31]A Uehara, Y Fujimoto, K Fukase, H Takada: Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44, 3100–3111 (2007)

  • [32]Y Kim, A Jo, D H Jang, Y-J Cho, J Chun, B-M Min, Y Choi: Toll-like receptor 9 mediates oral bacteria-induced IL-8 expression in gingival epithelial cells. Immunol Cell Biol 90, 655–663 (2012)

  • [33]M J Szczepanski, M Czystowska, M Szajnik, M Harasymczuk, M Boyiadzis, A Kruk-Zagajewska, W Szyfter, J Zeromski, T L Whiteside: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69, 3105–3113 (2009)

  • [34]Z Sun, Q Luo, D Ye, W Chen, F Chen: Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer 11, 33 (2012)

  • [35]G Pannone, V Rodolico, A Santoro, L Lo Muzio, R Franco, G Botti, G Aquino, M C Pedicillo, S Cagiano, G Campisi, C Rubini, S Papagerakis, G De Rosa, M L Tornesello, F M Buonaguro, S Staibano, P Bufo: Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agents Cancer 7, 4 (2012)

  • [36]A M de Roda Husman, J M Walboomers, A J van den Brule, C J Meijer, P J Snijders: The use of general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76 (Pt 4), 1057–1062 (1995)

  • [37]B Gharizadeh, M Oggionni, B Zheng, E Akom, N Pourmand, A Ahmadian, K-L Wallin, P Nyrén: Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. J Mol Diagn 7, 198–205 (2005)

  • [38]K Zeljic, G Supic, N Jovic, R Kozomara, M Brankovic-Magic, M Obrenovic, Z Magic: Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis 20, 416–424 (2014)

  • [39]L D. Thompson: Squamous cell carcinoma variants of the head and neck. Curr Diagn Pathol 9, 384–396 (2003)

  • [40]P A Humphrey, L P Dehner, J D Pfeifer. The Washington Manual of Surgical Pathology. Eds: Lippincott Williams & Wilkins 2nd edition. (2008)

  • [41]W H Westra: The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol 6 Suppl 1, S48–54 (2012)

  • [42]W H Westra: The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 3, 78–81 (2009)

  • [43]J M Werner, C Lang, M N Scherer, S A Farkas, E K Geissler, H J Schlitt, M Hornung: Distribution of intrahepatic T, NK and CD3(+)CD56(+)NKT cells alters after liver transplantation: Shift from innate to adaptive immunity? Transpl Immunol 25, 27–33 (2011)

  • [44]M Scheffner, K Munger, J C Byrne, P M Howley: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 88, 5523–5527 (1991)

  • [45]C D Woodworth: HPV innate immunity. Front Biosci 7, d2058–2071 (2002)

  • [46]P A Pioli, E Amiel, T M Schaefer, J E Connolly, C R Wira, P M Guyre: Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect Immun 72, 5799–5806 (2004)

  • [47]R Chen, A B Alvero, D-A Silasi, K D Steffensen, G Mor: Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene 27, 225–233 (2008)

  • [48]X Yuan, Y Zhou, W Wang, J Li, G Xie, Y Zhao, D Xu, L Shen: Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis 4, e794 (2013)

  • [49]Y Zhu, J-M Huang, G-N Zhang, X Zha, B-F Deng: Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med 10, 77 (2012)

  • [50]S D Kundu, C Lee, B K Billips, G M Habermacher, Q Zhang, V Liu, L Y Wong, D J Klumpp, P Thumbikat: The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68, 223–229 (2008)

  • [51]W He, Q Liu, L Wang, W Chen, N Li, X Cao: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44, 2850–2859 (2007)

  • [52]M Scott, M Nakagawa, A-B Moscicki: Cell-Mediated Immune Response to Human Papillomavirus Infection. Clin Diagn Lab Immunol 8, 209–220 (2001)

  • [53]G La Ruche, B You, I Mensah-Ado, C Bergeron, C Montcho, R Ramon, K Touré-Coulibaly, C Welffens-Ekra, F Dabis, G Orth: Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women. Int J Cancer 76, 480–486 (1998)

  • [54]G Bottley, O G Watherston, Y-L Hiew, B Norrild, G P Cook, G E Blair: High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27, 1794–1799 (2008)

  • [55]J M Andersen, D Al-Khairy, R R Ingalls: Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 74, 824–831 (2006)

  • [56]Z Q Yuan, L Bennett, M S Campo, L Nasir: Bovine papillomavirus type 1 E2 and E7 proteins down-regulate Toll Like Receptor 4 (TLR4) expression in equine fibroblasts. Virus Res 149, 124–127 (2010)

  • [57]Z Q Yuan, L Nicolson, B Marchetti, E A Gault, M S Campo, L Nasir: Transcriptional Changes Induced by Bovine Papillomavirus Type 1 in Equine Fibroblasts. J Virol 82, 6481–6491 (2008)

  • [58]P Hubert, L Herman, C Maillard, J-H Caberg, A Nikkels, G Pierard, J-M Foidart, A Noel, J Boniver, P Delvenne: Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 21, 2765–2775 (2007)

  • [59]J Laurson, S Khan, R Chung, K Cross, K Raj: Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31, 918–926 (2010)

  • [60]F Zhou, G R Leggatt, I H Frazer: Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS J 278, 955–963 (2011)

  • [61]W Li, X-M Deng, C-X Wang, X Zhang, G-X Zheng, J Zhang, J-B Feng: Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer 20, 227–232 (2010)

  • [62]K B Vieira, D J Goldstein, L L Villa: Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Res 56, 2452–2457 (1996)

  • [63]V H Bermúdez-Morales, O Peralta-Zaragoza, J M Alcocer-González, J Moreno, V Madrid-Marina: IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol Med Rep 4, 369–375 (2011)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

TLR4 down-regulation identifies high risk HPV integration in head and neck squamous cell carcinomas

Giuseppe Pannone 1, Pantaleo Bufo 1, Mirella Pace 1, Silvia Lepore 2, Giuseppe M. Russo 1, Corrado Rubini 3, Renato Franco 4, Gabriella Aquino 4, Angela Santoro 5,*, Giuseppina Campisi 6, Vito Rodolico 7, Eduardo Bucci 8, Gennaro Ilardi 9, Massimo Mascolo 9, Francesco Merolla 9, Lorenzo Lo Muzio 10, Iole Natalicchio 11, Giuseppe Colella 12, Stefania Trino 2, Ilaria Laurenzana 2, Rosalia Leonardi 13, Paolo Bucci 8
Affiliations
Article Info

1 Department of Clinical and Experimental Medicine, Section of Pathological Anatomy, University of Foggia, Foggia, Italy

2 Laboratory of Preclinical and Translational Research, IRCCS-CROB, Oncological Reference Centre of Basilicata, Rionero in Vulture (PZ), Italy

3 Section of Pathological Anatomy, Polytechnic University of Marche, Ancona, Italy

4 Section of Pathological Anatomy, National Cancer Institute IRCCS ‘G. Pascale’ Foundation, Napoli, Italy

5 Department of Laboratory and Services, Section of Histopathology, Research and Care Foundation ‘Giovanni Paolo II’, Catholic University of Sacred Heart (UCSC), Campobasso, Italy

6 Department of Surgical, Oncological and Stomatological Disciplines (Di.Chir.On.S.), University of Palermo, Via del Vespro 129, 90127 Palermo, Italy

7 Department of Sciences for the Promotion of the Maternal and Childhood Health “G. D’Alessandro”, Section of Anatomic Pathology, University of Palermo, A.O.U. Policlinico “P. Giaccone”, Palermo, Italy

8 Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Napoli ‘Federico II’, Napoli, Italy

9 Department of Advanced Biochemical Sciences, Section of Anatomic Pathology, University of Napoli Federico II, Via S Pansini 5, Napoli, Italy

10 Department of Experimental and Clinical Medicine, Dental Clinic, University of Foggia, Foggia, Italy

11 Section of Clinic Pathology, OO.RR., Foggia, Italy

12 Department of Head and Neck Surgery, Second University of Naples, Naples, Italy

13 Department Medical-Surgical Specialties, Section of Oral Medicine, Policlinico, University of Catania, Catania, Italy

*Author to whom correspondence should be addressed.

 

Abstract

TLRs are main actors of the innate immune response against HPV. There are very few studies on the role of TLRs mediated HPV clearance in Head and Neck oncology. Our aim was to evaluate whether TLR4 expression identifies HPV infection and/or HR-HPV integration status in oral and oropharyngeal cancers. By immunohistochemistry we assessed TLR4 levels in OSCC. To detect viral integration or episomic status In situ hybridization for HPV-DNA and Pyro-sequencing techniques have been performed. The relationship between TLR4 expression with HPV infection status has been investigated. ISH HPV positive samples have reported lower levels of TLR4 intensity than negative samples (p = 0.002). There is no statistical correlation between TLR4 intensity and PCR HPV results (p > 0.0.5). Point-biserial correlation coefficient revealed significant association between TLR4 expression and HR-HPV integration status (p = 0.0001) and between TLR4 expression index and HR-HPV infection (p = 0.001). These data show that TLR4 down-regulation is strongly associated to both HPV-16 infection and its integration into the host DNA.

Keywords

  • TLR4
  • HPV
  • Head
  • Neck
  • Squamous Cell Carcinomas

References